Crossject: Publication of Clinical Data on ZEPIZURE®

Pharmaceutical company Crossject announces the publication of clinical data on its product ZEPIZURE® in the peer-reviewed journal Neurology and Therapy. This research, carried out in 2022, highlights the bioequivalence of ZEPIZURE® compared to Dormicum®, a drug used in Europe.

ZEPIZURE® uses the ZENEO® needle-free auto-injector to administer midazolam. The study shows low variability compared to intranasal administration methods, which represents a significant advantage. Rapid absorption of the drug would allow increased effectiveness from the first minutes following injection.

The study, carried out on 40 healthy subjects, evaluated the relative bioavailability of midazolam. The results confirm that ZEPIZURE® offers safe, effective and rapid administration, comparable in terms of safety and variability to traditional intramuscular injection.